Objective To analyze the application effect of pharmacists' participation in the maintenance and manage-ment of smart pharmaceutical platform.Methods The prescriptions of Shunde Hospital of Guangzhou University of Chinese Med-icine from January 2023 to June 2024 were divided into blank group(from January 2023 to March 2023,305 411 traditional man-ual prescriptions were reviewed)and control group(from January 2024 to March 2024).The original rule review of the smart pharmacy platform system was adopted,339 042 copies),and the experimental group(from April 2024 to June 2024,the rule review after pharmacists participated in maintenance management was adopted,317 902 copies).The prescription qualification rate,the proportion of unreasonable prescriptions,the false positive rate,the proportion of manual review prescriptions,and the rate of filling prescriptions were evaluated,and the management effectiveness of the three groups was compared.Results The qualified rate of prescription in the experimental group and the control group was 99.52％ and 99.60％,respectively,which were higher than 98.74％ in the blank group,and there was a difference between the experimental group and the control group(P＜0.05).Among the irrational prescription types in the experimental group,the proportion of unsuitable administration route,in-complete clinical diagnosis,unsuitable indications and unsuitable usage and dosage were 16.57％,29.42％,20.55％ and 33.46％,and 23.28％,15.74％,30.38％ and 30.50％ in the control group.There were significant differences between 40.08％,27.11％,19.91％ and 12.9％ in blank group(P＜0.05).The false positive rate and manual prescription review ra-tio of the experimental group were 0.40％ and 0.88％,respectively,lower than 0.70％and 1.10％of the control group,and the prescription return rate of 0.78％ was higher than 0.10％ of the control group(P＜0.05).Conclusion Pharmacists' par-ticipation in the maintenance and management of smart pharmacy platform has high application value and can improve the drug safety of patients.

Objective To analyze the application effect of pharmacists' participation in the maintenance and manage-ment of smart pharmaceutical platform.Methods The prescriptions of Shunde Hospital of Guangzhou University of Chinese Med-icine from January 2023 to June 2024 were divided into blank group(from January 2023 to March 2023,305 411 traditional man-ual prescriptions were reviewed)and control group(from January 2024 to March 2024).The original rule review of the smart pharmacy platform system was adopted,339 042 copies),and the experimental group(from April 2024 to June 2024,the rule review after pharmacists participated in maintenance management was adopted,317 902 copies).The prescription qualification rate,the proportion of unreasonable prescriptions,the false positive rate,the proportion of manual review prescriptions,and the rate of filling prescriptions were evaluated,and the management effectiveness of the three groups was compared.Results The qualified rate of prescription in the experimental group and the control group was 99.52％ and 99.60％,respectively,which were higher than 98.74％ in the blank group,and there was a difference between the experimental group and the control group(P＜0.05).Among the irrational prescription types in the experimental group,the proportion of unsuitable administration route,in-complete clinical diagnosis,unsuitable indications and unsuitable usage and dosage were 16.57％,29.42％,20.55％ and 33.46％,and 23.28％,15.74％,30.38％ and 30.50％ in the control group.There were significant differences between 40.08％,27.11％,19.91％ and 12.9％ in blank group(P＜0.05).The false positive rate and manual prescription review ra-tio of the experimental group were 0.40％ and 0.88％,respectively,lower than 0.70％and 1.10％of the control group,and the prescription return rate of 0.78％ was higher than 0.10％ of the control group(P＜0.05).Conclusion Pharmacists' par-ticipation in the maintenance and management of smart pharmacy platform has high application value and can improve the drug safety of patients.

The Ly-6 and uPAR (LU) domain-containing proteins represent a large family of cell-surface markers. In particular, mouse Ly-6A/Sca-1 is a widely used marker for various stem cells; however, its human ortholog is missing. In this study, based on a systematic survey and comparative genomic study of mouse and human LU domain-containing proteins, we identified a previously unannotated human gene encoding the candidate ortholog of mouse Ly-6A/Sca-1. This gene, hereby named LY6A, reversely overlaps with a lncRNA gene in the majority of exonic sequences. We found that LY6A is aberrantly expressed in pituitary tumors, but not in normal pituitary tissues, and may contribute to tumorigenesis. Similar to mouse Ly-6A/Sca-1, human LY6A is also upregulated by interferon, suggesting a conserved transcriptional regulatory mechanism between humans and mice. We cloned the full-length LY6A cDNA, whose encoded protein sequence, domain architecture, and exon-intron structures are all well conserved with mouse Ly-6A/Sca-1. Ectopic expression of the LY6A protein in cells demonstrates that it acts the same as mouse Ly-6A/Sca-1 in their processing and glycosylphosphatidylinositol anchoring to the cell membrane. Collectively, these studies unveil a novel human gene encoding a candidate biomarker and provide an interesting model gene for studying gene regulatory and evolutionary mechanisms.
Humans ; Membrane Proteins/genetics* ; Pituitary Neoplasms/genetics* ; Biomarkers

OBJECTIVE: To identify the main active components in Ⅲ and their targets and explore the mechanism by which Ⅲ alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology. METHODS: The active components of Ⅲ and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways. RESULTS: A total of 102 active components were identified from Ⅲ. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD. CONCLUSIONS We preliminarily validated the prescription of Ⅲ and obtained scientific evidence that supported its use for treatment of proteinuria in CKD. The findings in this study provide a theoretical basis for further study of the mechanism of Ⅲ in the treatment of proteinuria in CKD.
Biological Availability ; Drugs, Chinese Herbal ; chemistry ; pharmacokinetics ; therapeutic use ; Humans ; Proteinuria ; drug therapy ; etiology ; metabolism ; Renal Insufficiency, Chronic ; complications ; metabolism

Objective To compare the clinical effects of periodontal treatment using periodontal endoscope with that of conventional treatment method for patients with periodontitis.Methods Eleven periodontal patients with moderate to advanced periodontal destruction were recruited and treated with scaling and root planing in a split-mouth design randomly with (test group) or without (control group)periodontal endoscope.Changes of such clinical parameters as plaque index (PLI),bleeding index (BI),probing depth (PD) and attachment loss (AL) before and after treatments as well as the difference between test and control groups were examined and compared.Results Both groups showed significant reductions in PD,BI and AL values at 6 weeks and 3 months after treatment (P ＜ 0.001).Only in the test group,for sites with PD≥6 mm at baseline,PD value ([4.0±1.2] mm) and AL value ([3.8±0.9] mm) at the end of 3 months were significantly lower than that at the end of 6 weeks (PD[4.4± 1.3] mm,P ＜ 0.00 I;AL[4.1± 1.1] mm,P ＜0.05).There were no significant differences between two groups at the baseline,at the end of 6 weeks and 3 months,respectively.However,for the sites with PD≥6 mm in anterior teeth,PD value in test group at the end of 3 months was significantly lower than that in control group ([3.2±0.9] mm vs [3.7±0.9] mm,P ＜ 0.05),while AL value tend to be lower ([2.9± 1.2] mm vs [3.6± 1.3] mm,P=0.061).Conclusions Periodontal treatment using endoscope is obviously effective,especially for the medium and long term prognosis of deep pockets and single rooted teeth.

AIM: Valproic acid (VPA) is a histone deacetylase inhibitor and is believed to have anti-tumor activity. The present study aims to investigate the effect of VPA on the, apoptosis and cytokine synthesis of human peripheral lymphocytes. METHODS: The activation and cytokine synthesis in lymphocytes in whole blood stimulated with phorbol dibutyrate (PDB) and ionomycin were evaluated with flow cytometry after fluorescent staining. The mitochondrial membrane potential was examined using 3, 3-dihexyloxacarbocyanine iodide [DiOC6(3)]staining. RESULTS: VPA at low doses (1 and 5 mmol/L) promoted CD69 expression in activated lymphocytes, whereas it turned to inhibit the expression of CD69 at a high dose (25 mmol/L). Meanwhile, VPA at low doses increased the mitochondrial membrane potential, while a high dose of VPA decreased it in activated lymphocytes. Furthermore, interleukin-2 (IL-2) synthesis was enhanced by low doses of VPA but inhibited by a high dose. However, interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) synthesis were dose-dependently enhanced by VPA as compared with those of PDB plus ionomycin-treated cells. CONCLUSION: VPA exerts biphasic effect on the further activation and apoptosis of human peripheral lymphocytes stimulated with mitogens and exhibits differential activity on the synthesis of several important cytokines in human lymphocytes.